AMAG Pharmaceuticals, a biopharmaceutical company, has announced that David Arkowitz, executive vice president (EVP), chief financial officer (CFO) and chief business officer, has resigned to pursue an opportunity at a private biofuels company. Arkowitz will remain with AMAG through 24 June 2011.
Edward English, AMAG’s vice president and corporate controller, will serve as interim CFO until a national search for a new CFO is complete. English has been with AMAG since 2007. From 1997 to 2007, he served in various senior financial positions with increasing responsibility at Praecis Pharmaceuticals, culminating in his appointment as vice president, CFO and treasurer in 2004.
English holds a BS in Business Administration from Georgetown University and a joint MS in Accounting and MBA from the Northeastern University Graduate School of Professional Accounting. English will continue to serve as the company’s vice president and corporate controller during his service as interim CFO.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.